The antiserum was produced against synthesized peptide derived from human FANCA. AA range:1121-1170
Alternative Names:
FANCA, FAA, FACA, FANCH, Fanconi anemia group A protein, Protein FACA
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity, they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group A. Alternative splicing results in multiple transcript variants encoding different isoforms. Mutations in this gene are the most common cause of Fanconi anemia. [provided by RefSeq, Jul
Immunohistochemistry: 1/100 - 1/300. ELISA: 1/5000. Not yet tested in other applications.
Immunohistochemistry analysis of paraffin-embedded human colon carcinoma, using FANCA Antibody. The picture on the right is blocked with the synthesized peptide.
* VAT and and shipping costs not included. Errors and price changes excepted
